Aldeyra Therapeutics
Aldeyra Therapeutics

Aldeyra Therapeutics

Pharmaceuticals
WebsiteInvestor RelationsSEC
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

$44.5M

Market Cap • 10/15/2026

2004

(22 years)

Founded

2014

(12 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,2

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,6

EPS

—

Market Cap

Market Cap

44,5M

EV

-467,7K

EV/Revenue

0

EV/EBITDA

0

EV/EBIT

0

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,4%

Total Yield

-0,4%

Payout

0%

Retained Earnings

-492,9M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,3%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

-11,8%

CAGR Net Income 5Y

-13,1%

CAGR EPS 5Y

-18,5%

CAGR OCF 5Y

-9,9%

Leverage

N.D./EBITDA

1,9

Debt/Equity

0%

Current Ratio

4,9

Quick Ratio

4,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium